Despite all of these evidence-based therapies that can be used in lipid disorders, patients with DM or prediabetes can have a residual CV risk caused, among other things, by an increased level of triglyceride-rich lipoproteins (which can be noticed through a high non-HDLc), an increased Lp(a), inflammation, an additional thrombotic risk or the glucose metabolism impairment itself, with the latter being addressed especially through the treatment with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) and/or a sodium-glucose cotransporter-2 inhibitor (SGLT2i). This evidence concerns the gene GLP1R and prediabetes syndrome.